1 unchanged sentence
Recent Sales of Unregistered Securities
−Removed: We did not sell any securities that were not registered under the Securities Act during the three months ended June 30, 2020.
−Removed: Summary of Non-Employee Director Compensation Program.
−Removed: Consulting Agreement, dated as of J une 16, 2020, by and between Solid Biosciences Inc.
−Removed: 2020 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K (File No.
−Removed: 001-38360) filed with the SEC on June 18, 2020).
−Removed: Form of Stock Option Agreement under the 2020 Equity Incentive Plan.
−Removed: Form of Restricted Stock Unit Agreement under the 2020 Equity Incentive Plan.
+Added: On July 1, 2020, we issued a warrant to purchase 8,444 shares of our common stock, or the Warrant, to a consultant in consideration for services provided by the consultant.
+Added: The Warrant is exercisable at an exercise price of $2.92 per share and expires on July 1, 2025.
+Added: The shares issuable upon exercise of the Warrant vest upon the consultant’s achievement of certain specified milestones.
+Added: We offered and sold the Warrant pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act.
+Added: Except as stated in this quarterly report on Form 10-Q, we did not sell any securities that were not registered under the Securities Act during the three months ended September 30, 2020.
+Added: Collaboration and License Agreement, dated as of October 22, 2020, by and between the Company and Ultragenyx Pharmaceutical Inc.
+Added: Stock Purchase Agreement, dated as of October 22, 2020, by and between the Company and Ultragenyx Pharmaceutical Inc.
+Added: Investor Agreement, dated as of October 22, 2020, by and between the Company and Ultragenyx Pharmaceutical Inc
+Added: First Amendment, dated as of October 9, 2020, to the Exclusive Patent License by and between the Company and the University of Washington.
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
11 unchanged sentences
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
+Added: + Certain portions of this exhibit have been omitted because they are not material and would likely cause competitive harm to the Registrant if disclosed.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Solid Biosciences Inc.
−Removed: August 6, 2020
+Added: November 5, 2020
/s/ Ilan Ganot
1 unchanged sentence
(Principal Executive Officer)
−Removed: August 6, 2020
+Added: November 5, 2020
/s/ Jennifer Ziolkowski
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.